Monoclonal antibodies for the treatment of Ebola virus disease

Expert Opinion on Investigational Drugs

Volumn 25, Issue 11, 2016, Pages 1325-1335

  Moekotte, A L ^a   Huson, M A M ^a   van der Ende, A J ^b,c   Agnandji, S T ^d,e   Huizenga, E ^b,c   Goorhuis, A ^a,c   Grobusch, M P ^a,c,d,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Lion Heart Medical Center   (Sierra Leone)

^c Lion Heart Medical Research Unit   (Sierra Leone)

^d Centre de Recherches Médicales en Lambaréné CERMEL   (Gabon)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Ebolavirus disease; mAb114; MB 003; MIL 77E; monoclonal antibodies; therapy; ZMAb; ZMappTM

Indexed keywords

CROSS REACTING ANTIBODY; EPITOPE; FAVIPIRAVIR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 114; MONOCLONAL ANTIBODY MB 003; MONOCLONAL ANTIBODY MIL 77E; POLYCLONAL ANTIBODY; TKM 130803; TKM EBOLA; UNCLASSIFIED DRUG; ZMAPP; EBOLA VACCINE;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; HUMAN; MUTATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; DRUG DESIGN; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE OUTBREAKS; DRUG DESIGN; EBOLA VACCINES; EPITOPES; HEMORRHAGIC FEVER, EBOLA; HUMANS; MUTATION;

EID: 84992160850     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1240785     Document Type: Review

References (54)

1. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–293.
2. Centers of Disease Control and Prevention (CDC). Outbreaks Chronology:Ebola virus disease. [cited 2015 Nov11]. Available from:http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
3. A.M.Saez, S.Weiss, K.Nowak, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2014;7:17–23.
4. WHO Ebola response team. Ebola virus disease in West Africa - The first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481–1495.
5. WHO situation report – 28 April 2016. [cited 2016 May22]. Available from:http://www.who.int/csr/disease/ebola/situation-reports/archive/en/
6. A.Negredo, G.Palacios, S.Vázquez-Morón, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog. 2011;7;e1002304.
7. M.P.Kiley, E.T.Bowen, G.A.Eddy, et al. Filoviridae:a taxonomic home for Marburg and Ebola viruses? Intervirol. 1982;18:24–32.
8. J.H.Kuhn, S.Becker, H.Ebihara, et al. Proposal for a revised taxonomy of the family Filoviridae:classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155:2083–2103.
9. T.A.Bharat, T.Noda, J.D.Riches, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci USA. 2012;109:4275–4280.
10. D.R.Beniac, P.L.Melito, S.L.Devarennes, et al. The organisation of ebola virus reveals a capacity for extensive, modular polyploidy. PLoS ONE. 2012;7:e29608.
11. I.Messaoudi, G.K.Amarasinghe, C.F.Basler Filovirus pathogenesis and immune evasion:insights from Ebola virus and Marburg virus. Nature Rev Microbiol. 2015;13:663–676.
12. M.Mehedi, D.Falzarano, J.Seebach, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406–5414.
13. C.D.Murin, M.L.Fusco, Z.A.Bornholdt, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA. 2014;111:17182–17187.
14. H.Feldmann, T.W.Geisbert. Ebola haemorrhagic fever. Lancet. 2011;377:849–862.
15. Centers for Disease Control and Prevention (CDC). Bioterrorism agents/diseases. [cited 2016 Apr29]. Available from:http://emergency.cdc.gov/agent/agentlist.asp#e
16. M.P.Grobusch, B.J.Visser, J.Boersma, et al. Ebola virus disease:Basics the medical specialist should know. Neth J Crit Care. 2015;22:6–14.
17. World Health Organization. Ebola vaccines, therapies, and diagnostics - Questions and Answers. [cited 2016 Apr29]. Available from:http://www.who.int/medicines/emp_ebola_q_as/en/
18. M.D.Tapia, S.O.Sow, K.E.Lyke, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
19. S.T.Agnandji, A.Huttner, M.E.Zinser, et al. Phase 1 trials of rVSV ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–1660.
20. J.A.Regules, J.H.Beigel, K.M.Paolino, et al. A recombinant vesicular stomatitis virus ebola vaccine – preliminary report. N Engl J Med. 2015 Apr 1. [Epub ahead of print]. DOI:10.1056/NEJMoa1414216
21. K.Ewer, T.Rampling, N.Venkatraman, et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N Engl J Med. 2016;374:1635–1646.
22. A.M.Henao-Restrepo, I.M.Longini, M.Egger, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866.
23. S.Sridhar. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015;3:125–138.
24. D.Sissoko, C.Laouenan, E.Folkesson, et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial):a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.
25. J.Dunning, F.Sahr, A.Rojek, et al. Experimental treatment of ebola virus disease with TKM-130803:A single-arm phase 2 clinical trial. PLoS Med. 2016;13:e1001997.
26. T.W.Geisbert, A.C.H.Lee, M.Robbins, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference:a proof-of-concept study. Lancet. 2010;375:1896–1905.
27. T.R.Kreil. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerging Infect Dis. 2015;21:521–523.
28. J.Van Griensven, A.De Weiggheleire, A.Delamou, et al. The use of ebola convalescent plasma to treat ebola virus disease in resource-constrained settings:a perspective from the field. Clin Infect Dis. 2016;62:69–74.
29. L.Zeitlin, K.J.Whaley, G.G.Olinger, et al. Antibody therapeutics for Ebola virus disease. Curr Opin Virol. 2016;17:45–49.• Very concise overview on mAb cocktail development against EVD by one of the groups leading the field.
30. E.González-González, M.M.Alvarez, A.R.Márquez-Ipiña, et al. Anti-Ebola therapies based on monoclonal antibodies:current state and challenges ahead. Crit Rev Biotechnol. 2015;26:1–16.
31. D.Corti, J.Misasi, S.Mulangu, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351:1339–1342.• Monotherapy with mAB114 derived from plasma of a Kikwit 1995 EVD survivor protected a limited number of macaques when administered up to 5 days postchallenge.
32. J.A.Wilson, M.Hevey, R.Bakken, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664–1666.
33. E.Davidson, C.Bryan, R.H.Fong, et al. Mechanism of binding to ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol. 2015;89:10982–10992.• This paper elucidates the mechanism of action of monoclonal antibody cocktails.
34. X.Qiu, J.B.Alimonti, P.L.Melito, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol. 2011;141:218–227.
35. X.Qiu, G.Wong, J.Audet, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.•• Demonstration that ZMapp emerging from MB-003 and ZMab cocktails resulted in a 100% survival rate in a limited number of EVD-infected macaques when treated within 5 days postchallenge.
36. X.Qiu, J.Audet, M.Lv, et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med. 2016;8:329–333.•• MIL-77E fully protects NHPs when administered 3 days postchallenge with a lethal EBOV dose.
37. C.A.JanewayJr, P.Travers, M.Walport, et al. Immunobiology:the immune system in health and disease. 5th ed. New York:Garland Science; 2001.
38. G.G.OlingerJr, J.Pettitt, D.Kim, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109:18030–18035.• 60% of NHPs versus no controls survived EBOV infection with MB-003 administered up to 48 h postinfection.
39. J.Pettitt, L.Zeitlin, H.Kim do, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199ra113.•• EBOV-challenged NHPs survived when given MB-003 after onset of disease.
40. X.Qiu, J.Audet, G.Wong, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4:138ra81.•• The authors demonstrate that EBOV-infected NHPs may develop strong specific immune responses and survive following administration of ZMAb and interferon after disease onset.
41. X.Qiu, G.Wong, L.Fernando, et al. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5:207ra143.
42. X.Qiu, J.Audet, G.Wong, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013;3:3365.•• Of NHPs which survived EBOV disease when challenged and administered ZMAb; 100% and 60%, respectively, survived when rechallenged at week 10 or 13, respectively.
43. N.Petrosillo, E.Nicastri, S.Lanini, et al. Ebola virus disease complicated with viral interstitial pneumonia:a case report. BMC Infect Dis. 2015;15:432.
44. M.Schibler, P.Vetter, P.Cherpillod, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease:a case report. Lancet Infect Dis. 2015;15:1034–1040.
45. G.M.Lyon, A.K.Mehta, J.B.Varkey, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402–2409.
46. E.Nakayama, A.Yokoyama, H.Miyamoto, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol. 2010;11:1723–1728.
47. J.P.Chippaux. Outbreaks of Ebola virus disease in Africa:the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis. 2014;20:44.
48. D.M.Pigott, N.Golding, A.Mylne, et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg. 2015;109:366–378.
49. W.Furuyama, A.Marzi, A.Nanbo, et al. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep. 2016;6:20514.
50. A.I.Flyak, X.Shen, C.D.Murin, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016;164:392–405.
51. F.W.Holtsberg, S.Shulenin, H.Vu, et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies:protection against ebola and Sudan viruses. J Virol. 2015;90:266–278.
52. A.I.Flyak, P.A.Ilinykh, C.D.Murin, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 2015;160:893–903.
53. Z.Y.Keck, S.G.Enterlein, K.A.Howell, et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2015;90:279–291.
54. G.Wong, X.Qiu, G.G.Olinger, et al. Post-exposure therapy of filovirus infections. Trends Microbiol. 2014;22:456–463.